Thyme Care

🎗️ For Breast Cancer Awareness Month, we’re spotlighting a challenge that often goes unseen: how breast cancer care is measured and reimbursed. Many breast cancer treatments are guided by something called HER2—a protein that helps doctors decide how aggressive a tumor is and which therapies to use. But HER2 isn’t just used to guide care. It’s also used to help determine how much a provider gets paid. At Thyme Care, in partnership with American Oncology Network , we looked at how this plays out in Medicare’s value-based model—and found two issues: 1️⃣ The categories used to define HER2 are outdated. That means when doctors use newer therapies (like for HER2-low disease), the model may not recognize it—leading to inaccurate cost estimates and possible financial penalties. https://lnkd.in/g7RdnATe 2️⃣ Practices are still required to manually report HER status—even though this can be intuited through claims-based logic. Workflow simplification allows care teams to focus on patient care, not administrative reporting. https://lnkd.in/g3FBNRV6 Our findings, presented at ASCO Quality 2025, show a better way: use real-time treatment data to reduce burden, improve accuracy, and ensure care teams are supported, not slowed down. Breast cancer care has advanced. The systems around it should, too. #ASCOQLTY25 #BreastCancerAwareness

💡 The future of case management isn’t about rebuilding what exists—it’s about supplementing it through integrated partnerships. Traditional models weren’t built for the complexities of cancer care. That’s where oncology care navigation steps in—personalized, proactive, and seamlessly connected. With EHR-integrated platforms, care teams gain real-time insights while also providing proactive member-reported outcomes, where patient risks are flagged before they escalate. By enhancing case management, oncology navigation unlocks new value for both members and organizations: https://hubs.li/Q03vs_Pp0

We’re heading to HLTH 2025 in Las Vegas, October 19–22! 🎰 Our Thyme Care team Jesse Waldron, Bradford Diephuis, Peter McMullan, Mark Lombardi, DSc and Nate Schlack will be onsite connecting with healthcare innovators and payers shaping the future of healthcare: https://lnkd.in/dChrCpxS If you’re attending, we’d love to meet and exchange ideas on how collaboration and integration can transform the cancer care experience — for patients, providers, and payers alike. Get in touch with us here: https://lnkd.in/g3sct43J

Congratulations to our investor, Town Hall Ventures, on their new fund! We are thrilled to be on the journey with you as we continue to partner to make cancer care more accessible and affordable for people everywhere.

🌵 We’re thrilled to welcome Jeffrey Lovesy as our new Senior Vice President and General Manager of Commercial Partnerships. 💊 Based in sunny Phoenix, Arizona, Jeff brings more than 25 years of experience in oncology and pharmaceutical leadership, including senior roles at Eagle Pharmaceuticals, Heron Therapeutics, Cardinal Health, and Flatiron Health. He’s built a career around strengthening provider partnerships and advancing smarter, more sustainable approaches to therapeutic access and affordability. 🏌️♂️ When it’s not 120 degrees in Phoenix, you can find Jeff golfing, spending time with family, including his wife Alyssa and their three kids, and enjoying everything Arizona has to offer. 🤝 Jeff is no stranger to our leadership team. He’s worked with Robin Shah and Bobby Green, M.D. Green in past chapters of his career and is excited to join Thyme Care at such a pivotal time in our growth. His leadership will help expand our partnerships with community oncology practices and advance innovative value based drug strategies that make cancer care more accessible and affordable for patients nationwide. We couldn’t be more excited to have him on board! Read more here: https://lnkd.in/d8a2q6hw

Thyme Care had a great time at the National Association of ACOs (NAACOS) Fall Conference 2025 in Washington, D.C. last week! It was wonderful getting to meet so many forward-thinking leaders and discuss how an oncology-specific approach to value-based care can drive better member outcomes and reduced costs for ACOs. Our CEO & Co-founder Robin Shah joined the Investor Panel, emphasizing how sustainable value-based models depend on deep integration with local providers, thoughtful provider enablement to prevent fragmentation, and a focus on improving the comprehensive patient experience — not just financial performance. For those we didn’t get a chance to chat with, we’d love to connect! If you’re interested in learning more, reach out to us here: https://lnkd.in/g3sct43J

Thyme Care’s Care Team doesn’t just focus on treatment— we provide whole-person support that addresses all the factors affecting a member's journey. 💜 Specifically trained for oncology navigation and care, our multidisciplinary Care Team engages members early in their cancer journey and supports them through treatment and beyond, addressing clinical and non-clinical member needs in close coordination with their oncologist. Learn more about our Care Team here: https://lnkd.in/et67uMG9

What if we could deliver the same life-saving cancer treatment, with less waste and tailored to each individual? Smarter care delivery means examining every step of the care experience, including how we dose and administer medications. Our latest research, presented at the ASCO Quality Care Symposium, explores weight-based dosing of pembrolizumab, a widely used immunotherapy. Instead of giving every patient the same fixed amount, weight-based dosing tailors the treatment to the individual – often leading to more affordable options with the same clinical efficacy. In a real-world setting across American Oncology Network network of community oncology practices, we found that weight-based dosing was not only safe and effective, but it also reduced unnecessary drug use and potential side effects, and supported more sustainable care in value-based models like Medicare’s EOM. This is a win for patients, for practices, and for the healthcare system. It’s a small shift that reflects a bigger idea: Better care doesn’t always mean more care. It means the right care, thoughtfully delivered. https://lnkd.in/gdkAq6xp #ASCOQLTY25 Keshav Goel , Kesshi Jordan , Biqi Zhang , Alphan Kirayoglu. Lalan Wilfong, M.D. , Bobby Green, M.D. , Stephen G. Divers, Puneeth Indurlal, Samyukta Mullangi

🏛️Medicaid Expansion: Where a practice is located can unintentionally affect how it performs under value-based care. In our latest research presented at ASCO Quality 2025, our team at Thyme Care, in partnership with American Oncology Network , examined how practices in Medicaid expansion states compare to those in non-expansion states under the Enhancing Oncology Model (EOM). What’s the difference? Some states chose to expand Medicaid under the Affordable Care Act, increasing access to coverage for low-income patients. Others did not. That state-level policy decision shapes patient populations and the financial benchmarks that practices must meet. In the EOM, there are built-in adjustments for patients with lower incomes but who do not qualify for Medicaid (via the Low-Income Subsidy program), but for certain cancer types—like lung and prostate—those adjustments aren’t currently applied. 👉 The result? Practices in non-expansion states may face performance benchmarks that don’t fully reflect the needs or risk profiles of the patients they serve. 📣 Our takeaway: As CMS refines the model, adding consistent adjustments for all cancer types could help ensure a more equitable experience for participating practices across geographies. These kinds of refinements help align national policy with local realities and ensure the model supports both high-quality care and health equity. Thanks to the researchers Samyukta Mullangi, Alphan Kirayoglu , Kesshi Jordan , Puneeth Indurlal, Bobby Green, M.D. , Lalan Wilfong, M.D. , Stephen G. Divers for bringing this important topic forward. https://lnkd.in/gBjpapss #ASCOQLTY25